文献速递血管炎

ANCA相关性血管炎:近期发病机制见解与治疗进展

Recent pathogenetic insights and therapeutic advances in ANCA-associated vasculitis.
PubMed 文献 · Ann Rheum Dis · 2025-12-29

本文综述了抗中性粒细胞胞质抗体(ANCA)相关性血管炎在发病机制理解上的进展对治疗策略和疾病监测方法的影响。传统疗法仍是基础,但靶向生物制剂、补体通路抑制剂和新兴细胞治疗拓宽了治疗选择,以减少不良反应、降低糖皮质激素需求和增强疾病控制。然而许多患者仍面临频繁复发、进行性组织损伤和慢性生活质量损害,现有缓解定义低估了持续疾病活动度和影响,个性化管理需利用生物标志物预测复发风险、区分活动性疾病与残留损伤并指导治疗强度。

要点

  • 靶向生物制剂、补体通路抑制剂和细胞治疗拓宽了ANCA相关性血管炎的治疗选择。
  • 现有缓解定义低估持续疾病活动度和影响,残留症状解读在缺乏明显炎症时具有挑战性。
  • 个性化管理需利用生物标志物预测复发风险、区分活动性疾病与残留损伤并指导治疗强度。

核心结论

  • ANCA相关性血管炎优化诊疗需将治疗创新与关注患者重要结局(持久缓解、功能恢复和日常健康改善)相结合。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • 传统疗法仍是ANCA相关性血管炎治疗基础,靶向生物制剂、补体通路抑制剂和新兴细胞治疗拓宽了治疗选择。
  • 许多ANCA相关性血管炎患者仍面临频繁复发、进行性组织损伤和慢性生活质量损害。
  • 现有缓解定义低估持续疾病活动度和影响,残留症状解读在缺乏明显炎症时具有挑战性。

临床怎么用

  • 有效长期照护需抑制疾病活动并管理治疗相关并发症、合并症风险和患者体验结局。
  • 个性化管理可利用生物标志物预测复发风险、区分活动性疾病与残留损伤并指导治疗强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advances in the understanding of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis have influenced both treatment strategies and approaches to disease monitoring. While conventional therapies remain the foundation of care, introducing targeted biologics, complement pathway inhibitors, and emerging cellular treatments have broadened therapeutic options to minimise adverse effects, reduce glucocorticoid requirements, and enhance disease control. Nevertheless, many patients still face frequent relapses, progressive tissue damage, and chronic impairments in quality of life. Existing definitions of remission underestimate ongoing disease activity and impact, and interpretation of residual symptoms can be challenging, especially in the absence of overt inflammation. There is a growing interest in personalised management to address these limitations, using biomarkers to better predict relapse risk, differentiate between active disease and residual damage, and guide treatment intensity. Effective long-term care now requires suppression of disease activity and careful management of treatment-related complications, comorbidity risks, and patient-experienced outcomes. Optimising care in ANCA-associated vasculitis will depend on integrating therapeutic innovation with a sustained focus on outcomes that matter most to patients, including durable remission, functional recovery, and improved day-to-day well-being.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Sagy I, Jayne DRW. Recent pathogenetic insights and therapeutic advances in ANCA-associated vasculitis. Ann Rheum Dis. 2025. PMID: 41469274. doi:10.1016/j.ard.2025.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。